DanCann Pharma A/S Publishes Its Annual Report for 2023: A Year of Strategic Review and Future Focus on Capital Efficiency and Profitability
COPENHAGEN, Denmark, 15 May 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that The Board of Directors and the Chief Executive Officer of DanCann Pharma publishes the annual report of the year 2023. The annual report is available in this press release and on the website of DanCann Pharma.Financial highlights for 2023: · Revenue for 2023 amounted to DKK 6.07 million (2022: DKK 5.71 million). · Net loss in 2023 amounted to DKK -62.26 million (2022: DKK -16.06 million).* · As of December 31,